



July 1, 2019 (Updated July 10, 2019)

Comment to the questions raised in the media about the verdict published by the Uppsala District Court on June 14, 2019

C-RAD Imaging AB, a subsidiary of the C-RAD group, has had a dispute since December 2017 with a former employee, who has also been CEO of the same subsidiary. The dispute is about the question if C-RAD trade secrets have been revealed in connection with the employment of the employee being ended. In a previous trial of patent rights between the former CEO's new company Beamocular AB (now in bankruptcy), C-RAD won and it was clarified that the company owns the rights to a patent family regarding an invention termed "Patient Monitoring Radiation Machines". This verdict has previously been communicated. Now in another dispute the verdict has fallen to the defendant's favor. C-RAD has not yet decided if an appeal will be made*.

The company will pay for the counterparty's legal costs. The cost is a single payment and does not have a significant impact on C-RAD from a financial perspective nor on the company's freedom to operate.

C-RAD has had a series of disputes concerning patent rights with the company Beamocular. C-RAD and Beamocular are also involved in another legal dispute. C-RAD filed a patent entitlement lawsuit against Beamocular with the Patent and Market Court in Stockholm on May 22, 2017. In this case C-RAD claims the ownership rights of the invention described in the patent application "Ionizing radiation detecting device" from Beamocular. The ownership in the rights of the patent does not have a significant impact on the company's long-term strategy as the patent is not utilized at the moment. The verdict will be announced no later than July 5, 2019**.

Updates July 10

*C-RAD filed an appeal on July 4, 2019.

** Publication of the verdict has been postponed by the court and is expected to be announced on July 26, 2019.

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm. For more information on C-RAD, please visit <http://www.c-rad.com>

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com